French SME specialised in innovative intranasal vaccine development is looking to join consortia in the HORIZON-HLTH-2026-01-DISEASE-04 call

We are a French biotech SME based in northern France, specialized in the development of prophylactic and therapeutic vaccines against infectious diseases.

Our proprietary platform relies on GMP-grade maltodextrin nanoparticles that enable nasal delivery of antigens (subunit or inactivated pathogens). This technology facilitates efficient passage through the mucosal barrier and significantly enhances immunogenicity and overall vaccine efficacy, elicing a potent T-cell response.

The company’s expertise spans both veterinary and human vaccines targeting parasites, viruses, bacteria, and fungi.

The company is currently advancing a first-in-class Toxoplasma gondii vaccine into human clinical trials following extensive vaccination campaigns in non-human primates. The human health pipeline also includes vaccine candidates targeting bacterial, parasitic, and viral diseases, with promising results obtained in preclinical studies.

In the veterinary field, the company has licensed the first therapeutic vaccine against canine leishmaniasis. Its veterinary pipeline also includes prophylactic vaccines against parasitic diseases (e.g. bovine neosporosis), bacterial infections (avian colibacillosis, bacterial diseases in fish), and a therapeutic vaccine against a fungal infection (feline sporotrichosis).

We are seeking collaborative partners to co-develop new prophylactic or therapeutic vaccines or to enhance existing formulations for both human and veterinary use. The nanoparticle platform supports mucosal administration of antigens derived from inactivated pathogens without the need for added adjuvants. We have extensive experience in nanoparticle–antigen formulation, physicochemical characterization, and preclinical immunogenicity evaluation in mouse models, including both humoral and cellular immune responses.

We benefited from European and international funding programs, including EuroNanoMed III (Project ID: 2019-131; Acronym: RuNNing) and IDRC InnoVet-AMR 1.0 and 2.0 for antibacterial vaccine development.

We aim to join a consortium of scientific and industrial partners interested in evaluating nasal and mucosal vaccine administration routes for human or veterinary applications and is particularly seek partners with access to relevant animal challenge models.